Press release
Big Pharma Outlook 2026
ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports.
Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%.
Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2026. A healthy launch portfolio will bolster growth as Big Pharma reaps the reward of breakthrough products as the result of recent industry innovation. By delving deeper into revenue trends, therapy area performance, and strategic drivers, this analysis is vital to understanding how Big Pharma will navigate headwinds in order to steer towards robust growth.
For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/big-pharma-outlook-2026
Key Highlights from this Datamonitor Healthcare Report:
• Big Pharma prescription drug sales are forecast to grow to $351bn by 2026 at a compound annual growth rate of 0.8%
• Number one company in 2021: Pfizer sustains top ranking in prescription drug sales out to 2021
• Number one company in 2026: Roche out-performs Pfizer out to 2026
• Pharmavitae Index: Roche tops the index with a score calculated from 9 different metrics based on portfolios sales, pipelines, growth prospects and financials
• Most valuable product: Keytruda will become the highest selling product with global sales forecast at $9bn
• Most lucrative therapy area: Oncology will maintain the largest proportion of Big Pharma prescription sales out to 2026.
• Most valuable class: PD-1/PD-L1 inhibitors will continue to build momentum out to 2026
• Pipeline launch analysis: Big Pharma’s launch portfolio is set to add $58.3bn in revenues out to 2026
To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41337
Key questions answered
Revenue Analysis
• Which will be the best performing companies out to 2026?
• Which companies will propel revenue growth over the forecast period?
• How will Big Pharma perform across the US, 5EU, Japan and RoW regions?
• Which companies will have leading market share gains and market share losses?
• Explore the Pharmavitae Analytics Index and how the portfolio compares against specific criteria
Therapy area analysis
• What are the detailed competitive dynamics at play in the oncology, metabolic and, infectious diseases markets?
• Which companies are building leadership in specific therapy area?
• How are late-stage pipelines positioned and what are the most-coveted launch products?
• How many new blockbuster positions will Big Pharma carve out to 2026?
• Which therapy areas will experience the largest growth and decline?
Lifecycle analysis
• What are Big Pharma’s relative growth rankings?
• Which companies are reliant on pipeline launches to drive growth?
• Which companies will be most affected by future biosimilar and generic erosion out to 2026?
• How much is expected to be wiped off of Big Pharma’s expiry portfolio?
Pipeline analysis
• What are the most coveted pipeline assets and which companies have the most valuable launch portfolios?
• Which Big Pharma companies have the largest late-stage pipelines?
• How does therapy area concentration for Big Pharma compare to the rest of the industry?
• How is Big Pharma concentrated in regards to therapy area in late-stage assets?
Strategy analysis
• How is Big Pharma using licensing deals to propel growth and in what therapy areas are deals concentrated?
• How is Big Pharma capitalizing on immuno-oncology using M&A and dealmaking?
• Can data transform pharmaceutical R&D to maintain a supply of innovative treatments?
• From R&D investment to externalization: where is Big Pharma maximizing value?
About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-1947
abigail@reportsworldwide.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Big Pharma Outlook 2026 here
News-ID: 806644 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
